Contact
searchSearch
HMP Global

Drug Recalls News

News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network
News
Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
08/20/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug...
08/20/2026
Pharmacy Learning Network
News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network
News
Dicyclomine Hydrochloride Recalled Due to Empty Capsules
08/13/2026
Rebecca Amrick
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has...
08/13/2026
Pharmacy Learning Network
News
Cyclophosphamide Injection Recalled Due to the Presence of Steel Particles
08/13/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug...
08/13/2026
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use